{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.3157.4020",
  "meta" : {
    "versionId" : "14",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "Yale Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-06-03"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2020-08-21"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4020",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.3157.4020"
    }
  ],
  "version" : "20200821",
  "name" : "FibrinolyticTherapy",
  "title" : "Fibrinolytic Therapy",
  "status" : "retired",
  "experimental" : false,
  "date" : "2022-03-08T01:02:00-05:00",
  "publisher" : "Yale",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: The purpose of this value set is to represent concepts for fibrinolytic therapy used in the treatment of ST-segment elevation myocardial infarction (STEMI).),(Data Element Scope: This value set may use a model element related to Medication, Laboratory Test and Measurement.),(Inclusion Criteria: Includes RXNORM codes that represent medications and LOINC codes that represent administration and measurement of fibrinolytic therapy for STEMI treatment.),(Exclusion Criteria: No exclusions.)",
  "compose" : {
    "include" : [
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4019"
        ]
      },
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4018"
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:a6215517-081a-4edd-821c-373df78ddddb",
    "timestamp" : "2024-06-14T16:03:45-04:00",
    "total" : 22,
    "contains" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "1804799",
        "display" : "alteplase 100 MG Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "1804804",
        "display" : "alteplase 50 MG Injection"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "21464-3",
        "display" : "Plasminogen activator urokinase type [Presence] in Tissue"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "313212",
        "display" : "tenecteplase 50 MG Injection"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "43636-0",
        "display" : "Plasminogen activator tissue type [Presence] in Platelet poor plasma by Chromogenic method"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5971-7",
        "display" : "Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5972-5",
        "display" : "Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay --20 minutes post venistasis"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5973-3",
        "display" : "Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay --10 minutes post venistasis"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5981-6",
        "display" : "Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex [Mass/volume] in Platelet poor plasma by Immunoassay"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5982-4",
        "display" : "Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex [Mass/volume] in Platelet poor plasma by Immunoassay --20 minutes post venistasis"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5983-2",
        "display" : "Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex [Mass/volume] in Platelet poor plasma by Immunoassay --10 minutes post venistasis"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5986-5",
        "display" : "Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5987-3",
        "display" : "Plasminogen activator tissue type [Mass/volume] in Platelet poor plasma by Chromogenic method"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5988-1",
        "display" : "Plasminogen activator tissue type [Mass/volume] in Platelet poor plasma by Chromogenic method --10 minutes post venistasis"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5989-9",
        "display" : "Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method --10 minutes post venistasis"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "5990-7",
        "display" : "Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method --20 minutes post venistasis"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "763138",
        "display" : "reteplase 10 UNT Injection"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "88659-8",
        "display" : "Timing of thrombolytic administration in relation to cardiac arrest"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "LP16885-3",
        "display" : "Plasminogen activator tissue type Ag"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "LP16889-5",
        "display" : "Plasminogen activator tissue type-Plasminogen activator inhibitor 1 complex"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "LP16891-1",
        "display" : "Plasminogen activator tissue type"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.77",
        "code" : "LP265990-4",
        "display" : "Timing of thrombolytic administration in relation to cardiac arrest"
      }
    ]
  }
}
